Advisor Group’s DIPLOMAT PHARMACY, INC. DPLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
$0 Sell
120
-3,670
-97% -$17.2K ﹤0.01% 5571
2019
Q3
$18K Buy
3,790
+767
+25% +$4.29K ﹤0.01% 4044
2019
Q2
$19K Hold
3,023
﹤0.01% 4023
2019
Q1
$18K Sell
3,023
-1,432
-32% -$14.8K ﹤0.01% 4049
2018
Q4
$61K Sell
4,455
-267
-6% -$4.5K ﹤0.01% 3051
2018
Q3
$91K Buy
4,722
+812
+21% +$17.3K ﹤0.01% 2827
2018
Q2
$99K Sell
3,910
-27
-0.7% -$630 ﹤0.01% 2532
2018
Q1
$79K Sell
3,937
-684
-15% -$16K ﹤0.01% 2751
2017
Q4
$93K Buy
4,621
+676
+17% +$13.3K ﹤0.01% 2638
2017
Q3
$81K Buy
3,945
+2,403
+156% +$40.6K ﹤0.01% 2586
2017
Q2
$23K Buy
1,542
+387
+34% +$6.45K ﹤0.01% 3430
2017
Q1
$19K Sell
1,155
-4,889
-81% -$70.5K ﹤0.01% 3405
2016
Q4
$76K Buy
6,044
+2,430
+67% +$45.3K ﹤0.01% 2264
2016
Q3
$102K Buy
3,614
+629
+21% +$21.1K ﹤0.01% 1992
2016
Q2
$103K Buy
+2,985
New +$93.8K ﹤0.01% 1916

Other funds holding DPLO

Advisor Group's DPLO Position: Q4 2019 in Review

Advisor Group reduced its DIPLOMAT PHARMACY, INC. (DPLO) stake by 97% in Q4 2019, selling an estimated $17.2K and leaving 120 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5571.

Advisor Group first reported a position in DPLO in Q2 2016 and has held it in 15 quarters since. The position peaked at $103K in Q2 2016. 138 funds tracked by Wall St. Rank hold DPLO as of Q4 2019.

  • Advisor Group held 120 shares of DIPLOMAT PHARMACY, INC. worth $0 as of Q4 2019.
  • Advisor Group sold 3,670 DIPLOMAT PHARMACY, INC. shares in Q4 2019, an estimated $17.2K.
  • DIPLOMAT PHARMACY, INC. made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5571 holding.
  • Advisor Group first reported a position in DIPLOMAT PHARMACY, INC. in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's DIPLOMAT PHARMACY, INC. position peaked at $103K in Q2 2016.
  • 138 funds tracked by Wall St. Rank held DIPLOMAT PHARMACY, INC. as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.